4Ginter E, Simko V. Diabetes type 2 pandemic in 21st century [J]. BratislLekListy, 2010, 111(3): 134-137.
5Simon D. Epidemiologieal features of type 2 diabetes[J]. Rev Prat, 2010, 60(4): 469-473.
6Moore KB, Saudek CD. Therapeutic potential of dipeptidyl peptidase IV inhibitor in patients with diabetes mellitus[J]. Am J Ther, 2008, 15(5) : 484-491.
7Sivertsen J, Rosenmeier J, Holst J J, et al. The effect of gluca- gon-like peptidel on cardio-vascular risk [ J ]. Nat Rev Cardiol, 2012, 9(4) :209 -22.
8Mu J, Woods J, Zhou Y P, et al. Chronic inhibition of dipeptidy peptidase-4 with a sitagliptin analog preserves pancreatic 13-cellmass and function in a rodent model of type 2 diabetes[ J]. Diabe- tes ,2006,55 ( 6 ) : 1695 - 1704.
9Flock C, Baggio L L, Longuet C, et al. Incretin receptors for glu- cagon-like peptide 1 and glucose-dependent insulin otropic poly- peptide are essential for the sustained metabolication of vildagliptin in mice[J]. J Diabetes, 2007, 56(4): 3006-13.
10Monami M, Lacomellil, Marchionni N, et al. Dipeptydil peptidase - 4 inhibitors in type 2 diabetes: ameta-analysis of randomized clini- cal trials[J]. Nun" Metab Cardiovase Dis,2010,20(4) : 224 -35.
